HCV感染者接受直接抗病毒药物治疗肝细胞癌风险变化

摘要/Abstract

摘要： 目的评价丙型肝炎病毒(HCV)感染者接受直接抗病毒药物(DAA)治疗肝细胞癌(HCC)风险变化。方法 2018年3月至2021年6月兰考第一医院接受治疗的HCV相关HCC病例73例。根据是否应用DAA治疗分为DAA组21例,非DAA组52例。比较HCV相关HCC病例基线资料、肿瘤学特征以及肿瘤分期情况(BCLC分期、TNM分期和CLIP评分)。结果 DAA组腹痛、腹水、下肢水肿、黄疸及乏力分别为16例(76.2%)、2例(9.5%)、1例(4.8%)、1例(4.8%)及1例(4.8%);非DAA组分别为17例(32.7%)、15例(28.8%)、 11例(21.1%)、9例(17.3%)及0,差异有统计学意义(P<0.05)。DAA组门静脉血栓10例(47.6%),高于非DAA组的12例(23.1%)(P<0.05);DAA组淋巴结转移6例(28.6%),高于非DAA组的3例(5.8%)(P<0.05)。DAA组BCLC 0、A、B、C、D分期分别为2例(9.5%)、2例(9.5%)、3例(14.3%)、9例(42.8%)及5例(23.8%),非DAA组分别为6例(11.5%)、19例(36.5%)、16例(30.8%)、4例(7.7%)及7例(13.5%),差异有统计学意义(P<0.05);DAA组TNMⅠ、Ⅱ、Ⅲ、Ⅳ分期分别为2例(9.5%)、3例(14.3%)、10例(47.6%)及6例(28.6%),非DAA组分别为27例(51.9%)、12例(23.1%)、8例(15.4%)及5例(9.6%),差异有统计学意义(P<0.05);DAA组CLIP评分0、1、2、3、4~6分为2例(9.5%)、5例(23.8%)、2例(9.5%)、3例(14.3%)及9例(42.8%),非DAA组分别为12例(23.1%)、15例(28.8%)、11例(21.1%)、13例(25.0%)及1例(1.9%),差异有统计学意义(P<0.05)。结论接受DAA治疗的CHC病例需要接受长期HCC监测。

关键词: 丙型肝炎病毒, 直接抗病毒药物, 肝细胞癌, BCLC分期

Abstract: Objective To compare the hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) in patients with or without receiving direct antiviral antivirals (DAAs). Methods Seventy three cases of HCV-related HCC enrolled from March 2018 to June 2021 were reviewed, including 58 males and 15 females, aged 56 (44, 76) years. They were divided into a DAAs group and a non-DAAs group according to whether DAAs treatment had been applied or not. The diagnosis of the disease met the requirements. The baseline data, oncological features and tumor stages (BCLC stage, TNM stage and CLIP score) of HCV-related HCC cases were collected and compared. Results There were 21 cases in DAAs group and 52 cases in non-DAAs group respectively. Abdominal pain, ascites, lower limb edema, jaundice and fatigue in DAAs group were 16 cases (76.2%), 2 cases (9.5%), 1 case (4.8%), and 1 case (4.8%), respectively, which were significantly different with those of 1 case (4.8%), 17 cases (32.7%), 15 cases (8.8%), 11 cases (21.1%), 9 cases (17.3%), 0 case (0) in non-DAAs group (P<0.05). There were 10 cases (47.6%) of portal vein thrombosis in DAAs group, which were significantly higher than those of 12 cases (23.1%) in non-DAAs group (P<0.05). There were 6 cases (28.6%) of Lymph node metastasis in DAAs group, which were significantly higher than those of 3 cases (5.8%) in non-DAAs group [ P<0.05]. The BCLC stages (0, A, B, C, D) in DAAs group were 2 cases (9.5%), 2 cases (9.5%), 3 cases (14.3%), 9 cases (42.8%) and 5 cases (23.8%) in each stage, while those in non-DAAs group were 6 cases (11.5%), 19 cases (36.5%), 16 cases (30.8%), 4 cases (7.7%), and 7 cases (13.5%), respectively, the difference was statistically significant (P<0.05). The TNM stages (Ⅰ, Ⅱ, Ⅲ, Ⅳ) in DAAs group were 2 cases (9.5%), 3 cases (14.3%), 10 cases (47.6%) and 6 cases (28.6%) in each stage, while those in non-DAAs group were 27 cases (51.9%), 12 cases (23.1%) and 8 cases (15.4%), respectively, the difference was statistically significant (P<0.05). The CLIP scores (0, 1, 2, 3, 4~6) of DAAs group were 2 (9.5%), 5 (23.8%), 2 (9.5%), 3 (14.3%) and 9 (42.8%), while those of non-DAAs group were 12 (23.1%), 15 (28.8%), 11(21.1%), 13(25.0%), and 1(1.9%), respectively, the difference was also statistically significant (P<0.05). Conclusion Chronic hepatitis C patients need long-term HCC monitoring even after DAAs treatment.

Key words: Hepatitis C virus, Direct acting antivirals, Hepatocellular carcinoma, BCLC stage

靳志恩, 徐攀, 袁宏伟, 徐敬江. HCV感染者接受直接抗病毒药物治疗肝细胞癌风险变化[J]. 肝脏, 2023, 28(6): 680-682.

JIN Zhi-en, XU pan, YUAN Hong-wei, XU Jing-jiang. A comparison between HCV-related hepatocellular carcinoma patients with or without direct acting antivirals treatment[J]. Chinese Hepatolgy, 2023, 28(6): 680-682.

参考文献

[1] Baumert TF, Berg T, Lim JK, et al. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology, 2019, 156(2):431-445.
[2] Cabral LKD, Grisetti L, Pratama MY, et al. Biomarkers for the detection and management of hepatocellular carcinoma in patients treated with direct-acting antivirals. Cancers (Basel), 2022, 14(11):2700.
[3] Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol, 2016, 65(4):719-726.
[4] Renzulli M, Buonfiglioli F, Conti F, et al. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur Radiol, 2018, 28(2):506-513.
[5] Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology, 2018, 155(2):411-421.e4.
[6] Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol, 2018, 69(2):345-352.
[7] Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol, 2017, S0168-8278(17)32273-0.
[8] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1): 后插33-后插52.
[9] Abdelaziz AO, Nabil MM, Abdelmaksoud AH, et al. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. Eur J Gastroenterol Hepatol, 2019, 31(1):75-79.
[10] Bruden DJT, McMahon BJ, Townshend-Bulson L, et al. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. Hepatology, 2017, 66(1):37-45.
[11] Okuda H, Nakanishi T, Takatsu K, et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer, 2000, 88(3):544-549.
[12] Liu C, Xiao GQ, Yan LN, et al. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol, 2013, 19(11):1811-1819.
[13] Han K, Tzimas GN, Barkun JS, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol, 2007, 21(1):39-45.
[14] Huang CM, Hu TH, Chang KC, et al. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents. Medicine (Baltimore), 2017, 96(46):e8696.
[15] Kwon JH, Yoo SH, Nam SW, et al. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: a multicenter study in Korea. J Med Virol, 2019, 91(6):1104-1111.